NCT05258279 2024-08-28
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
Juntendo University
Phase 2 Active not recruiting
Juntendo University
Innovent Biologics (Suzhou) Co. Ltd.
Shanghai Institute Of Biological Products
Sichuan University